.png)
Pgiam/iStock via Getty Images
TD Cowen initiated its coverage of Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy recommendation on Wednesday, noting undervaluation in the stock, given the rare disease drug developer's growth prospects.
Analyst Joseph Thome projected $1.08B in peak sales for Mirum's (NASDAQ:
English (US) ·